“AI should power the system — not replace the doctor.” – Myra Ahmed

In this episode of Compound Wisdom, Steve Sood sits down with Myra A., founder of Mochi Health, to break down where modern healthcare actually breaks — and why most solutions are solving the wrong layer of the problem.

Myra’s entry into healthcare was driven by a single question: where do patients fall out of care? That question led her to build Mochi Health — not as another telehealth brand pushing prescriptions, but as a marketplace connecting providers and pharmacies under one system.

Mochi’s model challenges the dominant telehealth approach. Instead of vertical integration and branding, it focuses on infrastructure — giving providers tools to operate, and patients the ability to choose, compare, and stay with the same doctor over time. Continuity, not transactions, becomes the core product.

The conversation then moves into the GLP-1 surge. Myra explains how initial skepticism around injectables quickly flipped into one of the largest demand waves in healthcare. What started as a niche treatment has now triggered a broader shift toward proactive care — with more drugs and categories already in development.

But with demand comes fragmentation. The discussion explores the rise of peptides and the “wild west” layer of the market — where consumers are increasingly ordering unregulated substances online. Myra highlights the gap between demand and oversight, and why testing infrastructure is still catching up.

On AI, the stance is clear. Most companies are applying AI at the wrong interface. Mochi uses it to remove operational burden — documentation, scheduling, billing — while keeping the doctor-patient relationship fully human. Efficiency is the goal, not replacement.

The episode closes with a broader view of where telehealth is heading — toward transparency, provider-led care, and systems that reduce friction rather than add layers. The next wave won’t be about more tools. It will be about better structure.

This is a grounded conversation on healthcare infrastructure, emerging drug markets, and the role of AI in rebuilding trust at scale.

Takeaways

Mochi Health is built as a marketplace, not a prescription-first platform

Continuity of care is a core differentiator in their model

Patients can choose and stay with providers long term

GLP-1 demand reshaped consumer expectations in healthcare

Future drug pipelines extend beyond weight loss into broader conditions

Oral alternatives currently lack strong efficacy compared to injectables

Peptides represent a growing but fragmented market

Unregulated demand is rising due to lack of access and transparency

Testing and compliance infrastructure is still developing

AI is most effective in back-office workflows

Documentation, billing, and scheduling are key AI use cases

Patient-facing AI still lacks trust and reliability

Provider efficiency directly improves patient outcomes

Telehealth growth is driven by pricing transparency gaps

Insurance systems often lack clarity for patients

Mochi integrates providers, pharmacies, and workflows into one system

Pharmacy onboarding includes testing and compliance validation

Women’s health and HRT demand is increasing on platforms

Future growth includes partnerships and device integrations

Healthcare is shifting toward system-level redesign, not surface fixes

Chapters

00:00 – Building provider and pharmacy infrastructure

02:00 – Why Mochi Health was created

05:30 – Marketplace vs traditional telehealth models

10:00 – Continuity of care and provider relationships

15:30 – The GLP-1 demand shift

21:00 – Future of weight loss and drug pipelines

26:00 – Oral vs injectable treatment limitations

30:30 – Peptides and emerging categories

35:30 – Risks of unregulated drug markets

40:00 – AI in healthcare systems

45:00 – Back-office automation vs patient interaction

50:00 – Provider tools and workflow optimization

55:00 – Pharmacy vetting and compliance

01:00:00 – Women’s health and HRT expansion

01:05:00 – Telehealth vs traditional care models

01:10:00 – Insurance and pricing transparency

01:15:00 – Future roadmap for Mochi Health

01:20:00 – Closing insights

Tags

#CompoundWisdom #MyraAhmed #MochiHealth #Telehealth #GLP1 #Peptides #HealthcareInnovation #DigitalHealth #AIinHealthcare #HealthcareSystems #PharmaTrends #ProviderLedCare #PatientExperience #HealthTech #FutureOfHealthcare